8-K: Orgenesis Secures $5 Million Equity Line to Advance Cell and Gene Therapy Platform

Orgenesis has entered into an agreement for a $5 million equity investment from Williamsburg Venture Holdings to support the development of its decentralized cell and gene therapy platform.

Summary

• Orgenesis Inc. has secured an equity purchase agreement with Williamsburg Venture Holdings for up to $5 million.
• The investment will be provided over a 24-month period, with an initial $750,000 upon the SEC's approval of a registration statement.
• The remaining $4.25 million will be available as needed by Orgenesis.
• The per share purchase price will be 90% of the average of the two lowest volume-weighted average prices (VWAP) over the five trading days before the purchase date.
• Orgenesis has the option to use an accelerated purchase notice, where the price is the lowest traded price on that day.
• In consideration of the put rights, the investor will receive 168,182 ordinary shares.
• The investor cannot acquire more than 9.99% of Orgenesis's outstanding ordinary shares.

Sentiment

Score: 6

Explanation: The document is moderately positive due to the secured funding, but tempered by the delisting from Nasdaq, the discount on share price, and the bankruptcy of some subsidiaries. The company is in a difficult position but the funding provides a lifeline.

Positives

• The $5 million investment provides Orgenesis with significant capital to advance its cell and gene therapy platform.
• The flexible funding structure allows Orgenesis to draw on capital as needed over the next 24 months.
• The accelerated purchase option provides Orgenesis with the ability to potentially raise capital at a higher price.
• The investment demonstrates confidence in Orgenesis's business model and technology.

Negatives

• The per share purchase price is at a 10% discount to the market price.
• The investor receives 168,182 ordinary shares as part of the agreement, which could dilute existing shareholders.
• The investor has the ability to purchase shares at a discount, which could negatively impact the share price.

Risks

• The company's common stock was delisted from the Nasdaq and is now trading on the OTCQX.
• The company has a history of losses and may not achieve profitability.
• There is a potential legal dispute with Germfree regarding an Asset Purchase and Strategic Collaboration Agreement.
• The company's Belgian subsidiaries have filed for bankruptcy.
• Liquidation activities have commenced at three Octomera subsidiaries.
• The company is reliant on its point-of-care cell therapy platform.
• The company's ability to manage potential disruptions and maintain sufficient working capital is a risk.

Future Outlook

Orgenesis plans to use the funds to accelerate the development and commercialization of its cell and gene therapy pipeline and its decentralized CGT platform.

Management Comments

• Vered Caplan, CEO of Orgenesis, stated that the investment aligns with their mission to bring innovative CGT solutions to market.
• The CEO also mentioned that the additional resources will aid in accelerating the development and commercialization of their pipeline.

Industry Context

This announcement comes as the cell and gene therapy sector is gaining increased attention and investment, with companies seeking to develop more accessible and cost-effective treatments. Orgenesis's focus on a decentralized approach aligns with a trend towards more localized and efficient production of these therapies.

Comparison to Industry Standards

• The 10% discount on the share price is a common practice in equity line agreements, providing an incentive for the investor.
• The 24-month commitment period is typical for such agreements, allowing the company to access capital as needed.
• The 9.99% ownership cap is a standard clause to prevent the investor from gaining control of the company.
• Comparable companies in the biotech space often use similar financing methods to fund research and development.
• The use of VWAP for pricing is a common method to determine a fair market price for the shares.

Legal Proceedings

• There is a potential legal dispute with Germfree regarding an Asset Purchase and Strategic Collaboration Agreement.
• Murray Bacal and Joseph Maganize have rights to have Orgenesis register 50,000 shares of Orgenesis stock each.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the company's increased financial stability.
• Customers may benefit from the accelerated development of new therapies.
• Suppliers may benefit from increased business with Orgenesis.
• Creditors may be impacted by the company's financial situation and the bankruptcy of some subsidiaries.

Next Steps

• Orgenesis will file a registration statement with the SEC.
• Orgenesis will begin drawing down on the equity line of credit as needed.
• Orgenesis will continue to develop and commercialize its cell and gene therapy platform.

Key Dates

Keywords

equity investment, cell and gene therapy, decentralized platform, biotech, OTCQX, funding, POCare platform, Williamsburg Venture Holdings, capital raise, VWAP